Back to Journals » Therapeutics and Clinical Risk Management » Volume 6

New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids

Authors Smith P

Published 4 February 2010 Volume 2010:6 Pages 59—63


Review by Single anonymous peer review

Peer reviewer comments 4

Paul F Smith

Department of Pharmacology and Toxicology, School of Medical Sciences, University of Otago, Dunedin, New Zealand

Abstract: Cannabinoids such as Cannabis-based medicinal extracts (CBMEs) are increasingly being used in the treatment of spasticity associated with multiple sclerosis (MS). They have been shown to have a beneficial effect on spasticity; however, this evidence is largely based on subjective rating scales. Objective measurements using the Ashworth scale have tended to show no significant effect; however, the validity of this scale has been questioned. The available clinical trial data suggest that the adverse side effects associated with using CBMEs are generally mild, such as dry mouth, dizziness, somnolence, nausea and intoxication. However, most of these trials were run over a period of months and it is possible that other adverse side effects could develop with long-term use. There may be reason to be concerned about the use of therapeutic cannabinoids by adolescents, people predisposed to psychosis and pregnant women.

Keywords: multiple sclerosis, spasticity, cannabinoids, Cannabis

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.